News 2023-06-23
[Important Notice] Porton Announcement Regarding the Change of Email Domain
Dear valued customers and partners,
We would like to extend our gratitude for your continuous support towards Porton Pharma Solutions Ltd. In order to further enhance the company's brand recognition, adapt to our global development strategy, improve communication efficiency, and protect each other's information security, we have decided to change our email domain name from porton.cn to portonpharma.com.
We will be discontinuing the use of the old email addresses and will automatically forward all emails sent to the old addresses to the new address in the coming weeks or so. To avoid any unnecessary delays, we strongly recommend that you start using the new email address to contact us starting from August 13, 2023.
We look forward to maintaining closer contact with you and achieving greater business success together. If you have any questions or need further assistance, please feel free to contact us at any time.
We apologize for any inconvenience caused by this change and appreciate your understanding!
Chinese website: www.porton.cn
English website: www. portonpharma.com
Others
More
News 2025-07-31
Porton Participates in Publishing an OPRD Paper, Demonstrating Strength in Drug Synthesis Technology
Metal catalytic and DoE technologies for the optimization of CT1812 synthesis routes

News 2025-07-31
NMPA Approves Jike Shu (Sebaloxavir Marboxil Tablets) for the Treatment of Uncomplicated Influenza in Adults
Self-developed novel PA endonuclease inhibitor anti-influenza drug Jike Shu (Sebaloxavir Marboxil Tablets) has officially received marketing approval from China's National Medical Products Administration (NMPA) for the treatment of uncomplicated influenza in adults.